<DOC>
	<DOCNO>NCT01832870</DOCNO>
	<brief_summary>This clinical trial design quantify immune response determine tolerability side effect sipuleucel-T give combination ipilimumab patient advanced prostate cancer .</brief_summary>
	<brief_title>Sipuleucel-T Ipilimumab Advanced Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Subjects advanced prostate cancer eligible receive sipuleucelT accordance FDA approve label sipuleucelT Subjects must understand sign inform consent form Subjects eligible receive sipuleucelT</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>